P2.01-54 Real-World PD-L1 Testing Patterns for Patients with Advanced Non-Small Cell Lung Cancer in Greece

Abstract

NSCLC diagnosis, who initiated systemic treatment between August 15th 2016 and August, 14th 2018. Result: A total of 472 patients were included in the registry. Demographic and first-line treatment information are presented in Table 1, along with the respective comparison between patients tested and not tested for PD-L1. Patients with ECOG PS 0-1 are more likely to be tested for PD-L1 status. Among patients tested for PD-L1, Dako 22C3 was the most commonly used testing assay (87.8%). The number of patients tested for PD-L1 increased between the two consecutive time periods (from August 15th 2016 to August, 14th 2018; Table 2).